The National Institutes of Health (NIH) has halted a study testing tecovirimat as a treatment for patients with mpox after the drug showed no significant difference in reducing the time to lesion resolution or in influencing pain compared with placebo.
While the drug posed no safety concerns, an interim data analysis of the STOMP study revealed that it did not meet the required efficacy standards. The study’s data safety and monitoring board (DSMB) recommended halting enrollment and
JANUARY 27, 2025